Literature DB >> 25115636

The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes.

Hirokazu Kakuda1, Junji Kobayashi, Masahiro Kakuda, Junichi Yamakawa, Noboru Takekoshi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25115636     DOI： 10.1007/s12020-014-0376-x

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  20 in total

1.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Authors:  N Matikainen; S Mänttäri; A Schweizer; A Ulvestad; D Mills; B E Dunning; J E Foley; M-R Taskinen
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

2.  Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.

Authors:  Keizo Nakaya; Naoto Kubota; Iseki Takamoto; Tetsuya Kubota; Hisayuki Katsuyama; Hiroyuki Sato; Kumpei Tokuyama; Shinji Hashimoto; Moritaka Goto; Takahito Jomori; Kohjiro Ueki; Takashi Kadowaki
Journal:  Metabolism       Date:  2013-02-08       Impact factor: 8.694

3.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

Authors: 
Journal:  Arch Intern Med       Date:  2001-02-12

4.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

Authors:  Mette Zander; Sten Madsbad; Jan Lysgaard Madsen; Jens Juul Holst
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

5.  Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.

Authors:  Nasib Ervinna; Tomoya Mita; Eisuke Yasunari; Kosuke Azuma; Rica Tanaka; Satoshi Fujimura; Dewi Sukmawati; Takashi Nomiyama; Akio Kanazawa; Ryuzo Kawamori; Yoshio Fujitani; Hirotaka Watada
Journal:  Endocrinology       Date:  2013-01-21       Impact factor: 4.736

6.  Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.

Authors:  T Wasada; K McCorkle; V Harris; K Kawai; B Howard; R H Unger
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

7.  Postprandial recruitment of neutrophils may contribute to endothelial dysfunction.

Authors:  A J H H M van Oostrom; T P Sijmonsma; C Verseyden; E H J M Jansen; E J P de Koning; T J Rabelink; M Castro Cabezas
Journal:  J Lipid Res       Date:  2002-12-16       Impact factor: 5.922

8.  Short-term effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men.

Authors:  Hirokazu Kakuda; Junji Kobayashi; Mio Nakato; Noboru Takekoshi
Journal:  Cholesterol       Date:  2013-12-10

9.  How hyperglycemia promotes atherosclerosis: molecular mechanisms.

Authors:  Doron Aronson; Elliot J Rayfield
Journal:  Cardiovasc Diabetol       Date:  2002-04-08       Impact factor: 9.951

10.  Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia.

Authors:  Triin Eglit; Inge Ringmets; Margus Lember
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240
View more
  12 in total

Review 1.  Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.

Authors:  Shinya Nishio; Mariko Abe; Hiroyuki Ito
Journal:  Diabetes Metab Syndr Obes       Date:  2015-03-18       Impact factor: 3.168

2.  The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study.

Authors:  Hirokazu Kakuda; Junji Kobayashi; Masaru Sakurai; Masahiro Kakuda; Noboru Takekoshi
Journal:  J Clin Med Res       Date:  2017-04-01

3.  Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.

Authors:  Wataru Yano; Noriyuki Inoue; Shiori Ito; Takahiro Itou; Misako Yasumura; Yasunobu Yoshinaka; Sumihiko Hagita; Moritaka Goto; Takashi Nakagawa; Keisuke Inoue; Sohei Tanabe; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2016-12-15       Impact factor: 4.232

4.  Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus.

Authors:  Yukari Chiba; Tadashi Yamakawa; Hirohisa Tsuchiya; Mari Oba; Daisuke Suzuki; Hirosuke Danno; Yoji Takatsuka; Hiroshi Shigematsu; Mizuki Kaneshiro; Yasuo Terauchi
Journal:  J Clin Med Res       Date:  2018-06-27

5.  Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.

Authors:  Atsuko Chihara; Atsushi Tanaka; Takeshi Morimoto; Mio Sakuma; Michio Shimabukuro; Takashi Nomiyama; Osamu Arasaki; Shinichiro Ueda; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2019-11-16       Impact factor: 9.951

6.  Determination of optimal cut-off points after a high-fat meal corresponding to fasting elevations of triglyceride and remnant cholesterol in Chinese subjects.

Authors:  Jin Xu; Yan-Qiao Chen; Shui-Ping Zhao; Ling Liu
Journal:  Lipids Health Dis       Date:  2019-11-25       Impact factor: 3.876

Review 7.  Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2015-09-29       Impact factor: 9.951

8.  Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.

Authors:  Akira Kurozumi; Yosuke Okada; Tadashi Arao; Takuya Kobayashi; Daisaku Masuda; Shizuya Yamashita; Yoshiya Tanaka
Journal:  J Diabetes Investig       Date:  2017-10-03       Impact factor: 4.232

9.  Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study.

Authors:  Hidetaka Hamasaki; Yasuteru Hamasaki
Journal:  World J Diabetes       Date:  2018-10-15

10.  Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.

Authors:  Moritaka Goto; Shinji Furuta; Satoko Yamashita; Hiroyuki Hashimoto; Wataru Yano; Noriyuki Inoue; Noriaki Kato; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2018-06-05       Impact factor: 4.232
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.